Tempus and Yale Announce Research Collaboration to Accelerate COVID-19 Test Development
Summary
CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, and the Yale School of Public Health announced a research collaboration to accelerate the development of COVID-19 diagnostic tests in the U.S. “Expanded at-home testing is critical to help control the pandemic and reduce future waves of COVID-19 infection,” said Joel Dudley, PhD, Chief Scientific Officer of Tempus. “Working with Tempus will allow us to conduct critical research and develop more testing options.” SalivaDirectTM received an Emergency Use Authorization from the FDA in August for the qualitative detection of nucleic acid from SARS-CoV-2 in saliva collected without preservatives in a sterile container from individuals suspected of COVID-19 by their healthcare provider, and the future iterations of SalivaDirectTM that Tempus and Yale are developing are expected to be subject to FDA review. SalivaDirect™ is a qualitative test for the detection of nucleic acid from SARS-CoV-2 in saliva collected without preservatives in a sterile container from individuals suspected of COVID-19 by their healthcare provider. SalivaDirect™ was developed by the Yale School of Public Health (YSPH) and has received an Emergency Use Authorization (EUA) from the United States Food and Drug Administration (FDA).
Classifications
AskAI Classifications
LabelsLinked Companies
